198
Participants
Start Date
June 20, 2013
Primary Completion Date
January 3, 2017
Study Completion Date
January 3, 2017
Secukinumab
Study treatment was provided in pre-filled 1 mL syringes.
Placebo
Placebo was provided in pre-filled 1 mL syringes.
Novartis Investigative Site, Brussels
Novartis Investigative Site, Sydney
Novartis Investigative Site, East Melbourne
Novartis Investigative Site, Liège
Novartis Investigative Site, Woolloongabba
Novartis Investigative Site, Duncansville
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Kiel
Novartis Investigative Site, High Point
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Bielefeld
Novartis Investigative Site, Birmingham
Novartis Investigative Site, Nashville
Novartis Investigative Site, Valencia
Novartis Investigative Site, Indianapolis
Novartis Investigative Site, Münster
Novartis Investigative Site, Bad Bentheim
Novartis Investigative Site, Barakaldo
Novartis Investigative Site, Skokie
Novartis Investigative Site, Heraklion, Crete
Novartis Investigative Site, Houston
Novartis Investigative Site, Phoenix
Novartis Investigative Site, Portland
Novartis Investigative Site, Ústí nad Labem
Novartis Investigative Site, Prague
Novartis Investigative Site, Arhus C
Novartis Investigative Site, Copenhagen NV
Novartis Investigative Site, Hellerup
Novartis Investigative Site, Athens
Novartis Investigative Site, Sabadell
Novartis Investigative Site, Barcelona
Novartis Investigative Site, London
Novartis Investigative Site, Staffordshire
Novartis Investigative Site, Dudley
Novartis Investigative Site, Birmingham
Novartis Investigative Site, Liverpool
Novartis Investigative Site, Newcastle upon Tyne
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY